相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Reconstruction of intestinal microecology of type 2 diabetes by fecal microbiota transplantation: Why and how
Kaijian Hou et al.
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES (2022)
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022
DIABETES CARE (2022)
Effect of Treatment of OSA With CPAP on Glycemic Control in Adults With Type 2 Diabetes: The Diabetes Sleep Treatment Trial (DSTT)
Eileen R. Chasens et al.
ENDOCRINE PRACTICE (2022)
Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment
Stefan Trapp et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
Dihe Cheng et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2022)
Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Qian Luo et al.
FRONTIERS IN MEDICINE (2022)
Dulaglutide Alleviates Alzheimer's Disease by Regulating Microglial Polarization and Neurogenic Activity
Yun Wang et al.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING (2022)
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
Nobuya Inagaki et al.
LANCET DIABETES & ENDOCRINOLOGY (2022)
Polyethylene Glycol Loxenatide Injection (GLP-1) Protects Vascular Endothelial Cell Function in Middle-Aged and Elderly Patients With Type 2 Diabetes by Regulating Gut Microbiota
Fengwu Chen et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2022)
Microbiota in health and diseases
Kaijian Hou et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects
Jonatan Bagger et al.
DIABETES (2021)
Gut Bacterial Characteristics of Patients With Type 2 Diabetes Mellitus and the Application Potential
Yanyan Que et al.
FRONTIERS IN IMMUNOLOGY (2021)
Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
Daria Ja'arah et al.
CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES (2021)
Treatment of Type 2 diabetes with Tianqi Jiangtang Capsule A systematic review and meta-analysis of randomized controlled trials
Chunli Piao et al.
MEDICINE (2020)
The Ratio of Oxidized Lipoprotein(a) to Native Lipoprotein(a) and the Endothelial Function in Patients with Type 2 Diabetes Mellitus
Kazuhiko Kotani et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study
Anum Saeed et al.
ATHEROSCLEROSIS (2019)
Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States
Reema Mody et al.
DIABETES OBESITY & METABOLISM (2019)
Mortality among people with type 2 diabetes in Germany
Thaddaeus Toennies et al.
DIABETOLOGE (2019)
Liraglutide, a human glucagon-like peptide-1 analogue, stimulates AKT-dependent survival signalling and inhibits pancreatic β-cell apoptosis
Katerina Kapodistria et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Thematic Review Series: Lipoprotein (a): Coming of Age at Last Lipoprotein (a): a historical appraisal
Karam M. Kostner et al.
JOURNAL OF LIPID RESEARCH (2017)
Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM)
Michael Willis et al.
PHARMACOECONOMICS (2017)
Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide
Carlos Alatorre et al.
DIABETES OBESITY & METABOLISM (2017)
Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery
Sergei Pechenov et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain
Manel Mata-Cases et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2016)
GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study
Kristine Faerch et al.
DIABETES (2015)
Role of rs6923761 gene variant in glucagon-like peptide 1 receptor in basal GLP-1 levels, cardiovascular risk factor and serum adipokine levels in naive type 2 diabetic patients
D. A. de Luis et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2015)
Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review
Patrick M. Zueger et al.
PHARMACOECONOMICS (2014)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Juris J. Meier
NATURE REVIEWS ENDOCRINOLOGY (2012)
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
Michael A. Nauck et al.
DIABETES (2011)
Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
Mathijs C. Bunck et al.
DIABETES CARE (2011)
Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials
John B. Buse et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Prolonged survival and improved glycemia in BioBreeding diabetic rats after early sustained exposure to glucagon-like peptide 1
Ofer Yanay et al.
JOURNAL OF GENE MEDICINE (2010)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: Importance of fatty acid length, polarity, and bulkiness
Kjeld Madsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans
JJ Meier et al.
DIABETOLOGIA (2006)
The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings
LJ Jenner et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2005)
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes
KB Degn et al.
DIABETES (2004)
Somatostatin restrains the secretion of glucagon-like peptide-1 and-2 from isolated perfused porcine ileum
L Hansen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2000)
分享论文
